Bright Minds Biosciences Inc. is an early-stage biopharmaceutical firm dedicated to creating serotonin (5-HT) based therapies. The company aims to enhance the well-being of individuals afflicted by debilitating and severe medical conditions. Its pipeline features a range of selective 5-HT receptor agonists, specifically targeting 5-HT2C, 5-HT2A, and combined 5-HT2C/A receptors. These compounds are being investigated for their potential in treating epilepsy, various pain conditions, and neuropsychiatric disorders. Bright Minds Biosciences has established partnerships with the National Institutes of Health for epilepsy research, the University of Texas Medical Branch to address impulse control issues like binge eating, and the Medical College of Wisconsin. Founded in 2019, the company operates from its headquarters in Vancouver, Canada.
